This was the stock's fourth consecutive day of gains.

Shares of ResMed Inc. RMD rose 1.46% to $239.95 Friday, on what proved to be an all-around positive trading session for the ...

We recently published a list of Jim Cramer Says The Day “Everything’s A Lot More Expensive” Is Coming & Discusses These 10 ...

All paying members at FNArena are being reminded they can set an email alert specifically for The Overnight Report. Go to ...

A strong session is expected for Aussie investors today. Here's what to expect. The post 5 things to watch on the ASX 200 on ...

Resmed was founded in Sydney in 1989, is now based in California, but is listed on both the ASX and Nasdaq. The company is the fourth largest healthcare firm on the ASX. On the US market ...

The CEO of ResMed, a $49b company which manufactures sleep devices to treat sleep apnea and other chronic respiratory conditions, on Thursday revealed the Trump Administration will not apply ...

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff ...

Nasdaq (NASDAQ:NDAQ) on Thursday delivered Q1 2025 earnings that exceeded Wall Street expectations as all three of its business recorded solid revenue growth during the quarter. The exchange also ...

ResMed Inc. (ASX: RMD) shares are charging higher on Thursday. In morning trade, the sleep disorder treatment company's shares are up 8% to $35.84. This follows the release of another strong ...

KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $274 from $269 on higher estimates, while keeping an Overweight rating on the shares. The firm believes investors ...

KeyBanc analyst Brett Fishbin maintained a Buy rating on Resmed (RMD – Research Report) today. The company’s shares closed yesterday at $214.44. Discover outperforming stocks and invest ...